Merck Stock ( NYSE:MRK )
On Thursday, February 2nd, before to market opens, Merck ( NYSE:MRK ) plans to release financial results for the fourth quarter .
The average analyst forecast is for earnings per share of $1.54 (down 14.4% year-over-year), on top of revenues of $13.66 billion (up 1.0% year-over-year).
During the previous two years, Merck stock has outperformed expectations for earnings per share (EPS) 88% of the time and sales 75% of the time.
There have been 10 positive adjustments and 5 negative revisions to EPS estimates during the previous three months. A total of seven increases and four decreases have been made to revenue forecasts.
After reporting third-quarter earnings above expectations, the company’s shares increased by 1.35% on October 27th. The sales effect of the COVID-19 tablet Lagevrio was more than offset by the success of the blockbuster cancer medicine Keytruda, which drove revenue to $5.3 billion and represented an increase of around 20% year over year.
With a return of 44% in 2022, Merck was the top-performing major U.S. pharmaceutical company.
The Merck stock was one of six Wells Fargo recommended to investors as “high-conviction names” for the first quarter.
Bank of America raised its rating on Merck stock in January, citing the company’s optimistic outlook for further growth in 2022 despite its heavy dependence on Keytruda.
Keytruda’s patent protection is set to expire by the end of 2040. Still, Merck is appar...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube